The impact of allograft injury time of onset on the risk of chronic lung allograft dysfunction (CLAD) remains unknown. We hypothesized that episodes of late-onset (≥6 months) allograft injury would produce an augmented CXCR3/ligand immune response, leading to increased CLAD. In a retrospective singlecenter study, 1894 transbronchial biopsy samples from 441 lung transplant recipients were reviewed for the presence of acute rejection (AR), lymphocytic bronchiolitis (LB), diffuse alveolar damage (DAD), and organizing pneumonia (OP). The association between the time of onset of each injury pattern and CLAD was assessed by using multivariable Cox models with time-dependent covariates. Bronchoalveolar lavage (BAL) CXCR3 ligand concentrations were compared between early-and late-onset injury patterns using linear mixed-effects models. Late-onset DAD and OP were strongly associated with CLAD: adjusted hazard ratio 2.8 (95% confidence interval 1.5-5.3) and 2.0 (1.1-3.4), respectively. The earlyonset form of these injury patterns did not increase CLAD risk. Late-onset LB and acute rejection (AR) predicted CLAD in univariable models but lost significance after multivariable adjustment for late DAD and OP. AR was the only early-onset injury pattern associated with CLAD development. Elevated BAL CXCR3 ligand concentrations during late-onset allograft injury parallel the increase in CLAD risk and support our hypothesis that late allograft injuries result in a more profound CXCR3/ligand immune response.
Introduction
Despite the severe impact of chronic lung allograft dysfunction (CLAD) on lung transplant survival (1), the pathogenesis is poorly understood. Because there are no effective treatments available for CLAD, the identification of risk factors is a key step toward both understanding CLAD pathogenesis and improving posttransplantation outcomes. There are numerous "nonalloimmune" (e.g. respiratory infections (2) (3) (4) (5) (6) (7) (8) (9) , gastroesophageal reflux (10, 11) , air pollution (12, 13) , autoimmune reactivity (14, 15) ), and "alloimmune" insults (e.g. acute cellular rejection (16) (17) (18) ) that challenge the lung allograft. However, the histopathologic allograft response patterns are generally limited to four: diffuse alveolar damage (DAD), organizing pneumonia (OP), lymphocytic bronchiolitis (LB), and a vascular mononuclear cell infiltration consistent with acute cellular rejection (AR).
Prior studies have established AR (16) (17) (18) (19) (20) (21) (22) (23) , LB (21, 25, (28) (29) (30) (31) , and DAD (32, 33) as major risk factors for CLAD development. Several of these studies have suggested a possible propensity for higher CLAD risk after late-onset injury, but the results have been inconsistent (18, 25, 27, 28, 32, 34) . Importantly, these earlier studies evaluated only one or two injury patterns (e.g. AR and LB) at a time and were limited by lack of multivariable adjustment. Further, the association between OP and CLAD development has not been well studied to date. In this study, we evaluated the effect of time of onset for all four allograft injury patterns concurrently by using appropriate Cox models for CLAD with time-dependent covariates.
We previously showed in animal models and human studies that the association between allograft injury and CLAD may be mediated in part by aberrant CXCR3/ligand biology (33, 35, 36) . CXCL9 (MIG), CXCL10 (IP10), and CXCL11 (ITAC) are interferon-c-inducible ELR-CXC chemokines (CXCR3 ligands) that signal through a shared receptor, CXCR3 (37, 38) . During the first few months posttransplantation, T cells differentiate from the na€ ıve to memory subclass depending on a number of factors (e.g. site of stimulation, antigen concentration, costimulation, and cytokine milieu) (39) (40) (41) . Importantly, CXCR3 ligand expression is augmented during the memory immune response and act as a potent chemoattractant for lymphocytes, particularly memory T cells (CD4, CD8) (42) (43) (44) .
Thus, we hypothesized that episodes of allograft injury occurring at later times posttransplantation would produce a more profound and sustained type I immune response, leading to increased fibroproliferation and CLAD. Given the role of CXCR3/ligand biology in perpetuating a type I immune response (35, 36, 45) , we further hypothesized that episodes of late allograft injury would be associated with increased bronchoalveolar lavage (BAL) CXCR3 ligand concentrations.
Methods
The study cohort consisted of all lung transplant recipients (LTRs) who received a first transplant at University of California Los Angeles (UCLA) between January 1, 2000, and December 31, 2010. LTRs received bronchoscopy with BAL and transbronchial biopsy (TBBX) at 1, 3, 6, and 12 months posttransplantation, as well as during episodes of clinical deterioration. One of three pulmonary pathologists interpreted the biopsy specimens according to International Society for Heart and Lung Transplantation criteria (AR and LB) (46, 47) and the International Multidisciplinary Consensus Statement on Idiopathic Interstitial Pneumonias (DAD and OP) (48) . LB was graded as present or absent until March 1, 2009 , and thereafter graded according to the revised 2007 International Society of Heart and Lung Transplantation criteria (0, B1R, B2R, or ungradable) (46) . Biopsy data were coded for the presence or absence of DAD, OP, LB, and AR (grade A1 or greater). TBBXs with two concurrent histopathologic findings were coded for the presence of both injury patterns.
Immunosuppression, antimicrobial prophylaxis, and treatment of AR were administered in accordance with the UCLA lung transplant protocols as described previously (7) . Serial spirometry was performed at least quarterly. CLAD was defined as a sustained drop of at least 20% in the forced expiratory volume in 1 s (FEV 1 ) from the average of the two best posttransplantation FEV 1 measurements (20, 49) . In a subset analysis of double-lung transplant recipients, CLAD was further classified as restrictive allograft syndrome (RAS) or bronchiolitis obliterans syndrome (BOS) based on Sato et al's 2013 definition using spirometry (50) and chest computed tomography (CT). RAS was defined as: D forced vital capacity % (DFVC%) / DFEV1% > 0.5 and chest CT showing ground-glass opacification, interstitial reticulation, or interlobular septal thickening. Recipients with CLAD who did not fulfill RAS criteria were considered to have the BOS phenotype. Those who did not have a chest CT within 3 months of CLAD diagnosis were excluded from this subset analysis.
To explore the effect of allograft injury time of onset on CLAD risk, univariable Cox models for CLAD were constructed with cumulative timedependent counts for the injury patterns. For example, a recipient was initially coded 0 for AR, 1 at the first episode of AR, 2 at the second episode, and so on. The data set contained one observation for each recipient with multiple columns for the time and value of TBBX results. The TBBX results were entered into the Cox model as cumulative timedependent repeated measures. Thus, both the timing and recurrence of the allograft injuries were taken into account. We began by constructing univariable Cox models with cumulative time-dependent counts for the injury patterns by using various time from transplantation cutoffs: ≥1 month, ≥3 months, ≥6 months, ≥9 months, and ≥12 months. In this exploratory analysis, an injury pattern increased the cumulative count only when it occurred after the specified cutoff time.
In keeping with prior studies, for all subsequent analysis, an injury pattern was considered "late onset" if the time from transplant was ≥6 months; otherwise, it was considered "early onset" (18, 25, 28) . Univariable Cox models for CLAD were constructed with time-dependent cumulative counts for the "early-onset" and "late-onset" forms of each allograft injury patterns. For example, a recipient was initially coded 0 for earlyonset AR and late-onset AR. At the first episode of "early-onset" AR, the early-onset AR variable increased from 0 to 1, and the late-onset AR variable remained at 0. At the first episode of "late-onset" AR, the late-onset AR variable increased from 0 to 1, and the early-onset AR variable remained at its prior value. The final multivariable model included all significant (p < 0.05) variables from the univariable models.
A subset of patients consented to the collection of BAL fluid for research purposes at the time of their bronchoscopies. Three 60-mL aliquots of isotonic saline were instilled into the subsegmental bronchus in the lingula, right middle lobe, or area of interest and pooled. After centrifugation, the supernatant was collected and stored unconcentrated at À80°C. CXCR3 ligand concentrations were measured using CXCL9, CXCL10, and CXCL11 bead assays (Millipore, Billerica, MA). The lower limit of detection for CXCL9, CXCL10 ,and CXCL11 were 19.2, 14.0, and 1.7 pg/mL, respectively. Given the high correlation among the three CXCR3 chemokines, a principal component (PC) analysis was performed to assess them in aggregate. The first PC of the three CXCR3 ligands was calculated as: PC = 0.357 logCXCL9 + 0.439 logCXCL10 + 0.386 logCXCL11. The PC accounted for 57% of the total chemokine variation. CXCR3 ligand concentrations were compared between early-and late-onset injury patterns by using linear mixed-effects models to account for repeated measurements from the same individuals. Analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).
Results

Histopathologic findings
In total, 1894 bronchoscopies with TBBXs were evaluated from 441 LTRs. There were 114 (6%) biopsy specimens with DAD, 169 (9%) biopsy specimens with OP, 565 (30%) biopsy specimens with LB and 391 (21%) biopsy specimens with AR. The AR biopsy specimens were graded as follows: 197 (50%) were grade A1, 129 (33%) were grade A2, 62 (16%) were grade A3, and 3 (1%) were grade A4. There were 303 TBBXs with concurrent injury patterns. AR and LB co-occurred most frequently (n = 193). OP occurred with LB (n = 79), AR (n = 45), and DAD (n = 30). DAD occurred with LB (n = 49) and AR (n = 25). Eight hundred thirty-eight (44%) TBBXs from 441 (100%) recipients had no evidence of histopathology and were classified as "healthy biopsy specimens." Using a predetermined 6-month cutoff for late onset, the number of early versus late episodes of the "healthy" DAD, OP, LB, and AR biopsy specimens were 507 versus 331, 65 versus 49, 111 versus 58, 357 versus 208, and 263 versus 128, respectively ( Figure 1 ). Table 1 shows demographic and clinical characteristics of recipients who had histopathologic allograft injury, stratified by whether they developed earlyversus late-onset injury. Most of the demographic and clinical variables were evenly distributed between recipients who developed early-versus late-onset injury. However, a higher proportion of biopsy specimens in the early period were for surveillance purposes compared with the late period: 821 (70%) of 1181 versus 246 (35%) of 713, respectively.
Risk of CLAD after allograft injury
To explore the impact of the time of onset of specific allograft injury patterns on CLAD risk, univariable Cox models were constructed with cumulative time-dependent counts for the injury patterns using various timefrom-transplantation cutoffs ( Figure 2 ). Overall, episodes of allograft injury occurring at later times posttransplantation were associated with increased CLAD risk. This trend was most notable for DAD and OP. The hazard ratio (HR) for an episode of DAD occurring after 1, 3, 6, 9, and 12 months was 2.8, 4.0, 4.9, 5.2, and 5.2, respectively. Similarly, the HR for an episode of OP occurring after 1, 3, 6, 9, and 12 months was 1.8, 2.5, 3.3, 4.3, and 5.8, respectively. The HRs for LB increased from 1.1, 1.3, 1.8, 2.4, and 2.4 during these time intervals. Compared with the other injury patterns, the HRs for AR remained relatively constant over time: 1.6, 1.5, 1.5, 2.0, and 2.1, respectively.
We further evaluated this relationship using Cox models with time-dependent counts for the each of the earlyand late-onset injury patterns as well as plausible demographic variables associated with poor outcomes (Table 2 ). In the univariable models for time to CLAD, the late-onset allograft injury DAD, OP, and LB were strongly predictive of CLAD development, while earlyonset forms of these injuries were not. The unadjusted HRs for CLAD for late-versus early-onset DAD, OP, and LB were 4.9 (p < 0.001) versus 1. Kaplan-Meier curves for freedom from CLAD were constructed and stratified by recipients with never versus late-onset versus early-onset allograft injury. Recipients who never had an episode of allograft injury had a median time to CLAD of 6.0 years ( Figure 3) . Those with an episode of late-onset DAD had a median time of 2.1 years, while those who had an episode of early-onset DAD had a median time of 3.6 years. Similarly, the median time to CLAD for those with late-and early-onset OP was 1.9 and 3.3 years, respectively. The median time to CLAD for recipients with late-and early-onset LB was 2.7 and 4.4 years, while the median time for those with late-and early-onset AR was 2.8 and 3.7 years, respectively. 
Risk of BOS and RAS after allograft injury
In a subset analysis among double-lung transplant recipients with chest CT results within 3 months of CLAD diagnosis, we explored the association between allograft injury and the CLAD phenotypes: BOS and RAS. Of the 202 double-lung transplant recipients with sufficient spirometric and radiographic data, 106 (53%) developed CLAD. Fiftyone (48%) of these recipients met RAS criteria, while the remaining 55 (42%) were categorized as BOS. The univariable models for time to RAS showed a similar pattern as time to CLAD but with higher HRs for all injury patterns. The late-onset injury patterns for DAD, OP, and LB were strongly predictive of RAS development, while the earlyonset forms of these injuries were not. The unadjusted HRs for RAS for late-versus early-onset DAD, OP, and LB were 16.0 (p < 0.001) versus 1.8 (p = 0.087), 6.6 (p < 0.001) versus 1.3 (p = 0.41), and 2.0 (p = 0.034) versus 1.5 (p = 0.21), respectively (Table 3 ). Both late-and early-onset AR were associated with RAS in univariable models with HRs: 2.0 (p = 0.026) versus 1.8 (p = 0.040), respectively. In the multivariable model, late-onset DAD (HR 6.2, 95% CI 2.0-18.8), late-onset OP (HR 3.2, 95% CI 1.1-8.8), and early-onset AR (HR 1.8, 95% CI 1.0-3.2) remained significant predictors of RAS, whereas both lateonset LB and late-onset AR lost significance. The univariable models for time to BOS showed a different pattern from the time to CLAD or RAS models: Late-onset LB was the only injury pattern associated with time to BOS with HR 2.1 (95% CI 1.1-3.9, Table 4 ).
BAL chemokines concentrations during early and late allograft injury
We previously showed that the association between allograft injury and CLAD may be mediated in part by aberrant CXCR3/ligand biology causing persistent mononuclear cell infiltration and further allograft injury. In the current study, we hypothesized that late episodes of allograft injury would be associated with a stronger CXCR3/ligand immune response, as measured as BAL CXCR3 ligand concentrations, corresponding to their increased CLAD risk.
We evaluated 779 BAL CXCR3 concentrations from 251 recipients. There was no difference in CXCL9, CXCL10, or CXCL11 concentrations between the late and early "healthy" biopsy specimens: The median CXCL9, CXCL10, and CXCL11 concentrations were 242 versus 291 pg/mL (p = 0.80), 120 versus 122 pg/mL (p = 0.43), and 81 versus 80 pg/mL (p = 0.80), respectively (Table 5 ). In contrast, late-onset allograft injury was associated with significantly higher BAL CXCR ligand concentrations compared with early-onset injury. The median CXCL9, CXCL10, and CXCL11 concentrations for lateand early-onset injuries were 1703 versus 623 pg/mL (p = 0.0006), 340 versus 207 pg/mL (p = 0.022), and 95 versus 82 pg/mL (p = 0.034), respectively. The PC analysis confirmed the increased CXCR3 ligand concentrations during late-onset allograft injury compared with earlyonset injury. The PC for the late-and early-onset allograft injury was 0.258 versus À0.056 (p = 0.0024). There was no difference in the PC between the late and early healthy biopsy specimens.
Discussion
Because the pathogenesis of CLAD remains poorly understood with no known effective therapies, the identification and avoidance of risk factors are critical. Previous studies have established AR, LB, and DAD as strong risk factors for CLAD development (17, 18, 21, 32, 33) . Several of these studies suggest a higher CLAD risk after lateonset injury, but the results have not been consistent (18, 25, 27, 28, 32, 34) . These prior studies evaluated only one or two injury patterns (e.g. AR and LB) at a time, and the association between OP and CLAD has not been well described. In this study, using time-dependent multivariable analysis controlling for all four allograft injury patterns, we sought to evaluate the significance of time of onset when considering the association between histopathologic injury and CLAD. We demonstrate that late-onset (≥6 months from transplantation) DAD and OP were strongly predictive of CLAD development, while the early-onset forms of these injuries have minimal effect on CLAD risk. Late-onset LB and AR were associated with CLAD in univariable models but lost significance after multivariable adjustment for DAD and OP. AR was the only early-onset injury pattern associated with CLAD in univariable and multivariable models.
DAD is the most severe form of acute lung allograft injury. However, the impact of DAD on CLAD risk has been evaluated in only a few studies. Fisher and colleagues found no difference in the incidence of CLAD among 291 LTRs after early-onset DAD (<7 days) compared with those without early-onset DAD (34). In contrast, Sato and colleagues showed increased CLAD risk after both early-(<3 months) and late-(≥3 months) onset DAD among 720 bilateral LTRs (32) . Specifically, they found that early-onset DAD increased the risk of BOS, while late-onset DAD increased the risk of RAS. We similarly found a strong association between late-onset DAD and RAS (HR 6.2, 95% CI 2.0-18.8) but no association between early-onset DAD and CLAD or BOS. Several studies have reported an association between primary graft dysfunction (PGD) and subsequent CLAD (51, 52) . The histopathology of PGD is often DAD; however, in our data set, PGD-associated DAD was likely not captured due to our surveillance protocol, which began at 1 month.
OP is arguably the second most severe form of acute allograft injury. However, there is a paucity of studies evaluating the association between OP and the development of CLAD. A study of 74 LTRs reported an association between OP and CLAD in univariable analysis but found no association after multivariable adjustment (31) . A larger study involving 230 LTRs similarly did not find OP to be an independent predictor of CLAD (28) . We previously demonstrated that when time of onset is ignored, OP does not increase the risk of CLAD development (33) . However, when OP is stratified by time of onset, it is one of the strongest predictors of CLAD, with HRs rivalling those of DAD. To our knowledge, this is the first study to show an association between OP and CLAD. The high HR of late-onset OP for CLAD development underscores the need for more studies to confirm this novel finding and determine treatment options to minimize the subsequent development of CLAD.
Several studies have suggested increased CLAD risk after episodes of late-onset AR and LB. A retrospective study of 259 LTRs by Hachem et al reported slightly higher HRs for CLAD after late-onset (>6 months) minimal (A1) rejection compared with early-onset rejection: HR 2.97 versus 2.28, respectively (18) . Similarly, a study involving 132 LTRs by Kroshus et al found increased CLAD risk among recipients with late-onset AR (>3 months) but not early-onset AR (27) . Husain and colleagues evaluated both AR and LB in a study of 134 LTRs and reported an association between both lateonset (>6 months) AR and late-onset LB with CLAD (25) . In contrast to these prior studies, which only evaluated one or two injury patterns at a time, we used timedependent multivariable analysis adjusting concurrently for all four allograft injury patterns. While late-onset LB and late-onset AR predict CLAD in univariable models, they lost significance after multivariable adjustment for two risk factors that were significantly stronger: lateonset DAD and late-onset OP. Of note, the HRs for CLAD correlate with the severity of the allograft injury pattern with the HRs for DAD > OP > AR/LB.
The mechanism responsible for this association between time of injury onset and CLAD remains unclear. We previously demonstrated that type I immune responses mediate in part the progression from allograft injury to CLAD (33, 35, 36, 53) . The allograft injury patterns likely represent a deleterious cycle of cell damage, type I immune response mediated in part by CXCR3/ligands, recruitment of injurious mononuclear cells, particularly memory T cells, into the allograft, causing further cell damage, CXCR3 ligand release, and eventual fibroproliferation (33, 35, 36) . Clinical studies by our group and others have shown increased BAL concentrations of the CXCR3 ligands during AR (35, 54) , LB (33), DAD (33) , and CLAD (33, 35, 55 ).
In the current study, we hypothesized that BAL CXCR3 ligand concentrations would be higher during episodes of late-onset allograft injury compared with early-onset injury, reflecting the increased risk of CLAD development. We evaluated 779 BAL CXCR3 ligand concentrations from 251 recipients and found significant elevations of all three CXCR3 ligands during the allograft injury patterns compared with healthy biopsy specimens. Further, late-onset injuries had markedly higher CXCR3 ligand concentrations compared with early-onset injuries, supporting our hypothesis that late-onset allograft injuries result in a more profound CXCR3/ligand immune response.
Several factors may be contributing to an augmented CXCR3/ligand response after late-onset allograft injury. At the time of surgery, our LTRs receive induction immunosuppression with thymoglobulin or basiliximab, which may lower CXCR3 ligand levels; both agents have a duration of action of 3 to 6 months (56, 57) . Alternatively, during the first few months posttransplantation, lymphocytes differentiate from the na€ ıve to memory subclass depending on a number of factors (e.g. site of stimulation, antigen concentration, costimulation, and cytokine milieu) (39) (40) (41) . The recruitment and stimulation of memory T cells, as opposed to na€ ıve T cells, during lateonset allograft injury may be producing a more profound and sustained type I immune response, leading to increased fibroproliferation and CLAD. The more vigorous immune response generated by the memory T cell recall response, compared with na€ ıve T cells, has been well established (58, 59) . Future studies characterizing the population of T cells (memory vs. naive) involved during late-and early-onset allograft injury are warranted.
AR was the only early-onset allograft injury that was associated with CLAD development. The pathogenesis of AR, however, is fundamentally different than that of the other injury patterns. While many cases of DAD, OP, and LB are initiated by exposure-related insults [e.g. aspiration, infection, pollution (13, 33, 60) ], AR represents an alloimmune response. Transplant recipients with early-onset AR may have had the early presence of circulating alloresponsive memory T cells. The development of pretransplantation allospecific memory T cells may occur due to allosensitization from prior pregnancies, blood transfusions, or infection. In fact, several studies in renal transplantation have demonstrated a strong association between pretransplantation donor-specific memory T cells and the development of early-onset AR (42) (43) (44) 61, 62) . Further research studying the mechanisms responsible for the association between AR and CLAD is clearly needed.
The major limitation of this study is the potential for confounding inherent to retrospective single center studies.
Patients with clinical deterioration may have undergone more frequent biopsies leading to a higher incidence of histopathologic findings. Our study design accounted only for allograft injuries that were captured by TBBX. Undoubtedly, there were episodes that were missed due to the infrequency of TBBX sampling and poor sensitivity for detecting the more subtle injury patterns (i.e. AR and LB). Treatments received for the allograft injury were also not taken into account. At our institution, patients routinely received augmented immunosuppression for AR but not for DAD, OP, or LB. Our study design included TBBXs performed for regular surveillance as well as clinical deterioration. Because there were more nonsurveillance bronchoscopies occurring later, allograft injuries occurring in the late-onset group were likely to be more severe and symptomatic, compared with the asymptomatic injuries observed on surveillance bronchoscopies. Unfortunately, stratification by clinical indication of the bronchoscopy was limited due to sample size. Finally, multivariable adjustment for all known risk factors for CLAD (e.g. primary graft dysfunction, donor-specific antibodies) was beyond the scope of this analysis.
This study extends our understanding of the association between CLAD and allograft injury, one of the most important risk factors associated with its development. We evaluated 1894 transbronchial biopsy specimens from 441 LTRs and, to our knowledge, this is the largest study to evaluate all four allograft injury patterns concurrently using appropriate Cox models for CLAD with timedependent covariates. We demonstrate for the first time that OP is a strong predictor of CLAD when time of onset is taken into account, with HRs surpassing both LB and AR. Further, this is one of the first studies to systematically evaluate pathophysiologic risk factors for the CLAD phenotypes: RAS and BOS. We show that the parenchymal and vascular injury patterns of DAD, OP, and AR predict RAS development, while the airway-centric injury pattern LB predicts BOS. Finally, this study evaluated 779 BAL CXCL9 concentrations from 251 LTRs and is the largest study to evaluate chemokine expression patterns during allograft injury.
In conclusion, we demonstrate the importance of time of onset when considering the association between allograft injury and CLAD. Late-onset DAD and OP markedly increase CLAD risk, specifically the restrictive phenotype RAS, whereas the early-onset forms of these injury patterns do not. Late-onset LB increases the risk of BOS, the obstructive phenotype of CLAD, whereas early-onset LB does not. AR was the only early-onset injury pattern that predicted CLAD/RAS development. Elevated BAL CXCR3 ligand concentrations during late-onset allograft injury parallel the increase in CLAD risk and support our hypothesis that late allograft injuries result in a more profound CXCR3/ligand immune response. However, the mechanism responsible for this augmented immune response during late allograft injury requires further study. The identification of key events that increase CLAD risk represent unique opportunities to better understand the immunologic processes responsible for CLAD development. Given the potential importance of time of onset when considering the association between allograft injury and CLAD, this finding should be validated in a larger multicenter study.
